86 filings
Page 3 of 5
8-K
swdp2m uw1ufsriy
2 Jun 20
Departure of Directors or Certain Officers
4:05pm
8-K
blm 9c5gmml3qi0t
11 May 20
Reata pharmaceuticals, inc. announces FIRST quarter 2020 financial RESULTS and provides an update on development programs
4:06pm
8-K
v3briwxa5bs
19 Feb 20
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and ProvideS an Update on Development Programs
4:03pm
8-K
wqae1
20 Dec 19
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:05pm
8-K
8s8028gxl3ih
14 Nov 19
Entry into a Material Definitive Agreement
5:00pm
8-K
w16ffqqvdhaxfd
12 Nov 19
Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs
6:50am
8-K
vasqvrv5pqsih4jbw
16 Oct 19
Entry into a Material Definitive Agreement
4:23pm
8-K
han1m3dd
15 Oct 19
Reata announces positive Topline results from the moxie Registrational trial of omaveloxolone in patients with friedreich’s ataxia
6:45am
8-K
inb89w gdv
10 Oct 19
Entry into a Material Definitive Agreement
6:51am
8-K
45nm8 otaty1deb
29 Aug 19
Reata Appoints Manmeet s. Soni as Chief Financial Officer; Jason D. wilson to assume new role AS EVP, Operations
12:00am
8-K
tyk8hkly
22 Aug 19
Entry into a Material Definitive Agreement
4:54pm
8-K
iiftq nwvc9p
8 Aug 19
Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs
6:44am
8-K
xpi8d
13 Jun 19
Departure of Directors or Certain Officers
4:05pm
8-K
mc6yxgznmu4ld5j3cp
9 May 19
Reata PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
6:49am
8-K
zb4gcw gzpytww3z
28 Feb 19
Reata PHARMACEUTICALS, Inc. annouNces fourth quarter and full year 2018 financials and operating results
6:50am
8-K
sjnswc2qw 7f
7 Nov 18
Reata Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results and an Update on Development Programs
7:05am
8-K
be1u8ge5qybt699vrlpy
25 Sep 18
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl In Iga Nephropathy and Type 1 Diabetic Chronic Kidney Disease
7:05am
8-K
fagjrfnkxb6spb yw
8 Aug 18
Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs
4:05pm
8-K
vwh02ekaw25m4s8m5
26 Jul 18
Entry into a Material Definitive Agreement
12:00am
8-K
ddu054g dc4
23 Jul 18
Results of Operations and Financial Condition
4:26pm